Solana Company Q2 FY2023 Earnings Call

· Earnings call transcript and AI-powered summary

  • Revenue Growth: Q2 2023 revenue was $256,000, up 115% YoY (from $119,000 in Q2 2022) and up 131% QoQ (from Q1 2023), primarily driven by U.S. sales under the now-terminated PTAP discount program.
  • PTAP Program Conclusion: The PoNS Therapy Access Program (PTAP) ended June 30, 2023. It successfully improved patient access and helped populate the MS registry with data critical for future third-party reimbursement efforts.
  • Reimbursement Strategy: Post-PTAP, U.S. sales will transition to cash-pay while Helius actively pursues reimbursement via CMS and private payers. DMEPOS accreditation obtained, enabling Medicare billing capabilities. Company optimistic about CMS’s proposed TCET reimbursement pathway for breakthrough devices like PoNS (designations in MS and stroke).
  • Clinical Trials Update:
    • PoNSTEP (MS Study): Six centers of excellence currently participating. Enrollment goal increased beyond initial 5 patients per site due to higher demand.
    • Stroke Study (Medical University of South Carolina): Trial expanded from 12 to 60 patients to support breakthrough designation and future FDA authorization pathway.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Good day, and thank you for standing by. Welcome to the Helius Medical Technologies, Inc. Q2 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Michelle Bilski, Investor Relations. Please go ahead. Michelle Bilski: Thank you, operator. Welcome to the second quarter 2023 earnings conference call for Helius Medical Technologies. This is Michelle Bilski of In-Site Communications, Investor Relations for Helius. With me on today's call are Dane Andreeff, Helius Medical's President and Chief Executive Officer; and Jeff Mathiesen, Chief Financial Officer. At this time, all participants have been placed in a listen-only mode. Please note that this call is being recorded, and access to the webcast can be obtained through the Investors section of the Helius website at www.heliusmedical.com. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including those identified in the Risk Factors section of our most recent annual report on Form 10-K and our quarterly reports on Form 10-Q. Such factors may be updated from time to time in our other filings with th

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional